Overview

Kristel Schorr is a partner and intellectual property lawyer with Foley & Lardner LLP. She is chair of the firm’s Chemical, Biotechnology & Pharmaceutical Practice.

Experience

Kristel counsels life science clients regarding all aspects of intellectual property, including due diligence analyses, invalidity, non-infringement and freedom to operate opinions, IP portfolio management, patent prosecution, post-grant and interference proceedings. Her legal practice spans a number of technical areas, including immunology, molecular and cell biology, protein chemistry, oligonucleotide therapeutics, oncology, small molecule pharmaceutical compositions and drug delivery systems, but her work often involves cell based therapeutics, and biologics such as antibodies and other large molecule receptor agonists and antagonists.

Kristel joined Foley in 2001 as a patent agent and law clerk after attending graduate school, and later as an associate. Kristel's graduate work was in the field of cancer biology, and the regulation of apoptosis in mammary epithelial cells in particular. She has also authored several scientific publications in this area.

Representative Matters

  • Represented Daiichi Sankyo in a successful Inter Partes Review of U.S. Patent 8,168,181 to Alethia Biotherapeutics (IPR 2015-00291)
  • Served as lead counsel in a successful interference matter for Athena Diagnostics (Patent Interference No. 106,015)
  • Represented Daiichi Sankyo Company, Limited as co-counsel in a successful interference proceeding (Patent Interference No. 106,070)

Recognition

Kristel was recognized by The Legal 500 for her patent prosecution work, including reexamination and post-grant proceedings (2016-2017), and patent licensing and transactional work (2012).

Publications and Presentations

  • “Patent Eligibility: Understanding How New 101 Decisions are Impacting the Industry,” American Conference Institute (ACI) Women Leaders in Life Sciences Law 2019 Conference, Boston, MA, July 25, 2019
  • “Biosimilars in the U.S., FDA Biosimilar Action Plan and Patent Challenges,” BIO KOREA 2019 International Convention, Seoul, South Korea, April 18, 2019
  • “AI in the Pharmaceutical & Life Sciences Industry” and “IP Issues Related to the Integration of AI Into Pharma Research, Diagnostics & Digital Healthcare,” Japan Pharmaceutical Manufacturers Association, Tokyo, Japan, December 20, 2018
  • “Immunotherapy at the Crossroads: Will Shifting Patent and Regulatory Trends Help or Hurt?” South San Francisco, CA, November 27, 2018
  • “Artificial Intelligence: The Next Technology Wave and Patent Strategies to Consider to Not Be Left Behind” and “'Pharma & Biotech Breakout:' Advanced Strategy for Protecting Personalized Medicine Inventions Based on The USPTO’s 2018 Vanda Guidance, FDA Labeling Requirements & New Joint Infringement Precedent / Updates on the CRISPR Patent Interference,” Foley's 2018 Tokyo IP Conference: Global Relationships in Flux – How Would You Redraw Your IP Strategy Map? Tokyo, Japan, October 11, 2018
  • “FDA Biosimilar Action Plan & Current IP Issues,” Changes in U.S. Biosimilar Market Seminar, Seoul, South Korea, September 2018
  • “The Use of Artificial Intelligence in Life Sciences/Healthcare and Licensing Considerations,” American Chamber of Commerce in Korea (AMCHAM) Joint Legal Affairs, Pharmaceuticals and Medical Devices Committee Meeting, Seoul, South Korea, May 9, 2018
  • “AI on the Move: Tackling Legal Challenges with Artificial Intelligence in High-Tech and Life Sciences,” Osaka, March 14, 2018/Tokyo, March 15, 2018
  • “Game Changers: How CAR-T and Cell Therapy Are Revolutionizing Cancer Immunotherapy,” Foley Webinar, December 7, 2017
  • “'Pharma & Biotech Breakout:' Hatch-Waxman and IPR Strategy Updates,” Foley’s 2017 Tokyo IP Conference: Global Impacts in Flux: Strategies for IP and Legal Leaders,” Tokyo, Japan, September 7, 2017
  • “Biotech Protection in the U.S., Canada, and EU: Is This a New Era?,” 2017 BIO World Congress, Montréal, Canada, July 24, 2017
  • “PTAB Practice Updates for Pharma and Biotech Companies,” MIP PTAB Forum 2017, New York, NY, May 16, 2017
  • “Thought Leaders Exchange for Regenerative Medicine and Cell Therapy: Bridging the Gap Between Spectacular Medical Promises and Business Realities,” Boston, MA, May 3, 2017
  • “U.S. Investment Strategies for Korean Life Sciences Firms,” SelectUSA Seminar at 2017 BIO KOREA, Seoul, South Korea, April 13, 2017
  • “Optimizing Use of Inter Partes Review (IPR) and Ex Parte Reexaminations as a Commercialization Strategy for Biologics and Biosimilars in the U.S.,” AMCHAM Joint Legal Affairs and Pharmaceutical Committee Meeting, Seoul, South Korea, March 16, 2017
  • “IPR Master Class Workshop Series - Session Two,” Tokyo, January 26, 2017
  • “CRISPR-Cas – Patent, Licensing and Recent Development,” Foley and Japan Bioindustry Association CRISPR Seminar, Tokyo, January 25, 2017
  • “IP Today: Capturing the Competitive Edge - Weighing the Impact of Change in the U.S. IP World,” Tokyo, September 8, 2016
  • “IP Today: Capturing the Competitive Edge: U.S. Patent Prosecution Seminar Series,” Tokyo, June 30, 2016/Osaka, July 1, 2016
  • “Supreme Court Declines to Review Sequenom Ruling,” Legal News: Intellectual Property, June 27, 2016
  • “Pharma & the PTAB,” PTAB Forum 2016, May 12, 2016
  • “The U.S. Market and Beyond: New IP Strategies for Success,” IP Today: Capturing the Competitive Edge Japan Program Series, Tokyo, Japan, September 29, 2015
  • “The Road Ahead For Kyle Bass's IPRs” Law360, August 2015
  • “Federal Circuit Holds Sequenom's Diagnostic Method Patent Invalid Under 101,” Foley & Lardner Legal News: Life Sciences, June 2015
  • “Patent Watch: Have the Biosimilar Floodgates Been Opened in the United States?” Nature Review, April 2015
  • “IP on the Cusp of the Next Evolution,” IP in the Reform Era 2014 Seminar Series, Tokyo, Japan, September 9, 2014
  • “America Invents Act: Law & Analysis,” Co-author, Wolters Kluwer Law & Business, 2014 Edition
  • “USPTO Finally Issues New Guidance on Patent Subject Matter Eligibility,” PharmaPatents, December 2014
  • “USPTO Issues Long–Awaited Revised Guidance on Patent Eligibility,” Foley & Lardner Legal News: Intellectual Property, December 2014
  • “USPTO Issues New Guidelines on Subject Matter Eligibility Under 35 USC 101 in View of Myriad and Prometheus,” Foley & Lardner Legal News: Intellectual Property, March 2014
  • “Supreme Court Holds Isolated Naturally Occurring DNA Cannot Be Patented, Sustains Patent-Eligibility of cDNA,” Foley & Lardner Legal News: Intellectual Property, June 2013
  • “Federal Circuit Again Upholds Patent-Eligibility of Myriad's Isolated DNA Claims, Holds Diagnostic "Analyzing" Claims Patent-Ineligible,” Foley & Lardner Legal News: Intellectual Property, August 2012
  • “Unanimous Supreme Court Invalidates Prometheus Personalized Medicine Claims,” Foley & Lardner Legal News: Life Sciences, March 2012
  • “The Biologics Price Competition and Innovation Act: Implications for Implementation in Light of FDA Draft Guidance,” Foley & Lardner Legal News: Life Sciences, February 2012 
  • “USPTO Issues Proposed Rules Packages to Implement America Invents Act,” Foley & Lardner Legal News: Intellectual Property, February 2012

Education

Kristel graduated from The George Washington University Law School (J.D., 2004), received her doctorate in medical physiology from the University of Maryland School of Medicine (Ph.D., 2000) and her undergraduate degree from The Pennsylvania State University (B.S., 1994).

Admissions and Professional Memberships

Kristel is a member of the District of Columbia Bar, an inactive member of the Maryland Bar, and is admitted to practice before the U.S. Patent and Trademark Office.